CooperCompanies stock steadies ahead of September 9 earnings update

Published on 09/07/2026 at 21:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CooperCompanies stock is trading below its 52-week peak as investors look toward the upcoming September 9, 2026 earnings release and recent quarterly margin trends in its contact lens and women’s health businesses.

Reinraum-Produktionsanlage für medizinische Geräte mit Technikern an Kontaktlinsen-Fertigungslinien — CooperCompanies Reinraum-Produktion US21664P1039 zeigt automatisierte Kontaktlinsen-Fertigungslinien mit optischer Qualitätsprüfung im sterilen Reinraumbereich, Illustration mit AI erstellt.

CooperCompanies stock (ISIN US21664P1039) is trading at USD 69.59 on the Nasdaq as of September 4, 2026, down 15.1% year to date from USD 81.96 at the beginning of 2026, with a 52-week range between USD 58.89 and USD 89.83 according to MarketBeat.

Upcoming earnings date sets the tone

According to an analysis by Trefis, CooperCompanies is scheduled to report its next earnings on September 9, 2026, a date that has become the key near-term catalyst for the stock as investors reassess growth prospects and valuation.

Market data compiled by MarketBeat show that CooperCompanies carries a consensus price target of USD 81.64, implying about 17.3% upside from the current USD 69.59 level as of September 4, 2026, highlighting that analysts still see room for appreciation despite the double-digit year-to-date decline.

Recent earnings and margin signals

In the most recently reported quarter covered in a U.S. earnings roundup, CooperCompanies posted earnings per share of USD 1.11 for what was labeled as its first quarter (Q1), slightly up from USD 1.10 in the prior-year quarter, illustrating modest bottom-line growth over the year-ago period.

The incremental increase of roughly 0.9% in EPS from USD 1.10 to USD 1.11 in that Q1 reporting period suggests that profitability is edging higher, even as the stock price has retreated 15.1% year to date compared with the broader gain of 13.3% for the S&P 500 and 11.2% for the health care sector ETF cited in the Trefis analysis.

Analyst views and valuation context

Analysts aggregated by MarketBeat assign CooperCompanies a consensus Hold rating based on a mix of strong buy, buy, hold and sell recommendations, with an average rating score of 2.35 on their scale, indicating a balanced view between supporters and skeptics of the stock at current levels.

The same data set shows that the market capitalization stands at about USD 13.57 billion at the USD 69.59 share price as of September 4, 2026, implying a price-to-earnings ratio of 58.97, a multiple that reflects expectations of continued earnings growth but also leaves the stock sensitive to any disappointment in the upcoming September 9, 2026 results.

Corporate actions and governance backdrop

In the company’s latest annual meeting-related filing, stockholders elected all nine director nominees, ratified KPMG LLP as independent auditor for the fiscal year ending October 31, 2026, and approved executive compensation on an advisory basis, according to a recent Form 8-K summary compiled by StockTitan.

Separately, insider transaction data from a Form 4 overview indicate that after a reported open-market purchase, one insider directly beneficially owns 236,151 CooperCompanies shares, underlining that at least some management or board-level investors have been willing to add to positions ahead of the new fiscal year.

Contact lenses remain a core driver

CooperCompanies is best known for its CooperVision business, which focuses on soft contact lenses for daily wear and specialty vision correction, a segment that remains a central revenue driver and a key reason investors watch volume growth and pricing power closely in each quarterly report.

Stock level and investor perspective

With the stock at USD 69.59 on the Nasdaq as of the close on September 4, 2026 and a 52-week high of USD 89.83, CooperCompanies stock is trading roughly 22.5% below its recent peak, a gap that frames the risk-reward balance for investors heading into the September 9, 2026 earnings release in light of the modest EPS growth recorded in the latest reported quarter and the consensus target of USD 81.64.